The Inter-American Society of Hypertension (IASH) is a non-profit organization devoted to the understanding, prevention, and control of hypertension and vascular diseases with emphasis on bridging basic, translational, and clinical research across the Americas.
Membership is extended to scientists, physicians, and health care providers from 20 different countries in the Americas, Europe, Australia, and Asia. Anyone interested in the field of hypertension, cardiometabolic risk factors, and cardiovascular diseases is welcome to join the society.
Sign up to receive our newsletter:
21st INTER-AMERICAN SOCIETY OF HYPERTENSION SCIENTIFIC SESSIONS AND 24 SESIONES CIENTIFICAS OF THE SOCIEDAD ARGENTINA DE HIPERTENSION ARTERIAL
April 20-22, 2017
The IASH had a joint meeting with the Argentinian Society of Hypertension (SAHA) in April 2017 in Mendoza, Argentina. The organizing IASH-SAHA committee sponsored a poster session dedicated to new investigators doing research in hypertension and cardiovascular diseases. In cooperation with the International Society of Hypertension (ISH), American Foundation for Hypertension Education and Research (AFHRE), and the American Heart Association Council on Hypertension (AHA COH) IASH granted 3 new investigators from Latin America with travel awards. The top 3 scored presenters were:
- Alexis A. Gonzales (Pontificia Universidad Catolica de Valparaiso, Chile; First place: $US 1,000)
- Cesar Romero (Henry Ford Hospital, Detroit, USA; Second Place: $US 750)
- Diahann Perdicaro (CONICET, Mendoza, Argentina; Third place: $US 500)
The IASH was very pleased to support the career advancement of these young talented investigators! Visit our photo album on Facebook (https://www.facebook.com/IASHonline) to check more pictures of the IASH activities during this scientific meeting.
THE SPRINT TRIAL: A RANDOMIZED TRIAL OF INTENSIVE VERSUS STANDARD BLOOD PRESSURE CONTROL
November 26, 2015
The SPRINT trial compared less-tight control with tight control of hypertension in patients with increased cardiovascular risk but without diabetes. The study included 4678 patients assigned to the intensive treatment of systolic blood pressure (target, <120 mm Hg) and 4683 patients assigned to standard treatment (target, <140 mm Hg). The authors concluded that among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group (NEJM, November 26, 2015).
DUAL RENIN ANGIOTENSIN SYSTEM BLOCKADE
July 10, 2015
Two studies evaluated the effect of lisinopril combined with telmisartan in early and late stage polycystic kidney disease. In late-stage polycystic kidney disease the rates of decline in the estimated GFR, urinary albumin excretion, and adverse events, including hyperkalemia and acute kidney injury, did not also differ significantly between two groups. Similar conclusions were derived from another published study in which lisinopril and telmisartan were employed in early stage of autosomal dominant polycystic kidney disease.
(Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Moore CG, Perrone RD; the HALT-PKD Trial Investigators. Angiotensin Blockade in Late Autosomal Dominant Polycystic Kidney Disease. N Engl J Med. 2014 Dec 11;371(24):2267-2276;
Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB; the HALT-PKD Trial Investigators. Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease. N Engl J Med. 2014 Dec 11;371(24):2255-2266)